
    
      This is a Phase 4, single center, open label, fixed-sequence, 2-way drug-drug interaction
      study.

      Each subject will qualify for entry into the study not more than 30 days before admission
      into the clinical unit. Subjects will check into the clinical unit on Day -1 for baseline
      assessments. There will be 1 treatment period, with each subject receiving a once daily dose
      of pitavastatin 4 mg on Days 1 through 5 and Days 12 through 16 and a once daily dose of
      darunavir/ritonavir 800 mg/100 mg on Days 6 through 16. On Days 1 through 4, 6 through 10,
      and 12 through 15, study drug will be administered 30 minutes before a standard breakfast. On
      Days 5, 11, and 16, subjects will fast at least 8 hours before receiving study drug and
      remain fasted for 4 hours after dosing.
    
  